Christopher N. Luscombe
GlaxoSmithKline (Ireland)(IE)GlaxoSmithKline (Brazil)(BR)
Publications by Year
Research Areas
Computational Drug Discovery Methods, Analytical Chemistry and Chromatography, Pharmacogenetics and Drug Metabolism, PI3K/AKT/mTOR signaling in cancer, Spectroscopy and Chemometric Analyses
Most-Cited Works
- → Getting physical in drug discovery II: the impact of chromatographic hydrophobicity measurements and aromaticity(2011)300 cited
- → The developability of heteroaromatic and heteroaliphatic rings – do some have a better pedigree as potential drug molecules than others?(2012)177 cited
- → Lead Optimization Using Matched Molecular Pairs: Inclusion of Contextual Information for Enhanced Prediction of hERG Inhibition, Solubility, and Lipophilicity(2010)130 cited
- → Increasing small molecule drug developability in sub-optimal chemical space(2013)101 cited
- → MELLODDY: Cross-pharma Federated Learning at Unprecedented Scale Unlocks Benefits in QSAR without Compromising Proprietary Information(2023)99 cited
- → On the mechanism of human intestinal absorption(2002)78 cited
- → Analysis of the Calculated Physicochemical Properties of Respiratory Drugs: Can We Design for Inhaled Drugs Yet?(2009)59 cited
- → Integrating in Silico and in Vitro Approaches To Predict Drug Accessibility to the Central Nervous System(2016)51 cited
- → Using Physicochemical Measurements to Influence Better Compound Design(2019)50 cited
- → QSAR workbench: automating QSAR modeling to drive compound design(2013)49 cited